Stockscreener 앱 받기
13.32
1.52%
0.115
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Published on: 2025-08-04 07:21:19 - jammulinksnews.com
What are analysts’ price targets for KalVista Pharmaceuticals Inc. in the next 12 monthsBuild wealth steadily with proven stock picks - jammulinksnews.com
What institutional investors are buying KalVista Pharmaceuticals Inc. stockRapid wealth creation - jammulinksnews.com
Is KalVista Pharmaceuticals Inc. stock overvalued or undervaluedMaximize your portfolio’s earning power - jammulinksnews.com
What analysts say about KalVista Pharmaceuticals Inc. stockInvest confidently with actionable market data - jammulinksnews.com
What are the technical indicators suggesting about KalVista Pharmaceuticals Inc.Unstoppable investment returns - jammulinksnews.com
When is KalVista Pharmaceuticals Inc. stock expected to show significant growthAchieve consistent profits with expert strategies - jammulinksnews.com
What drives KalVista Pharmaceuticals Inc. stock priceConsistently profitable trades - jammulinksnews.com
KalVista Pharmaceuticals Inc. Stock Analysis and ForecastUnlock exclusive investment alerts - jammulinksnews.com
What is the risk reward ratio of investing in KalVista Pharmaceuticals Inc. stockAdvanced Screener Growth Plan For Every Investor - jammulinksnews.com
What are KalVista Pharmaceuticals Inc. company’s key revenue driversAI Powered Tracker That Work - jammulinksnews.com
KalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines Agency - MSN
Published on: 2025-07-29 19:52:44 - metal.it
What makes KalVista Pharmaceuticals Inc. stock price move sharplyTriple Return Setup With Risk Control Explained - beatles.ru
Sebetralstat recommended for EU approval for treating HAE attacks - Angioedema News
What is the dividend policy of KalVista Pharmaceuticals Inc. stockBreakthrough investment results - jammulinksnews.com
KalVista Pharmaceuticals Faces Downgrade Due to Shrinking Market and Oral Competitor Threat - AInvest
KalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade) - Seeking Alpha
Kalvista Pharmaceuticals shares rise 1.17% after-hours following positive CHMP opinion for sebetralstat. - AInvest
EMA’s CHMP adopts five orphans - BioCentury
What analysts say about KalVista Pharmaceuticals Inc. stock outlookPhenomenal capital gains - jammulinksnews.com
New medicines recommended for approval by EMA’s CHMP - The Pharma Letter
KalVista receives CHMP opinion recommending sebetralstat marketing authorization - TipRanks
KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha
European regulator recommends approval of first oral HAE treatment - Investing.com
KalVista Pharma Announces Positive CHMP Opinion For Sebetralstat - Nasdaq
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks - Business Wire
US FDA Cancer Reviewers Heading For The Exits, Potentially Impacting Review Timelines - insights.citeline.com
Is KalVista Pharmaceuticals Inc. a good long term investmentRapid return acceleration - jammulinksnews.com
Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com
3.18%
자본화:
|
볼륨(24시간):